Niagen Bioscience Inc(NAGE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 6:10 PM ET (Korea 10/30 07:10)
Full metrics table
| Index | RUT | P/E | 13.28 | EPS (ttm) | 0.19 | Insider Own | 34.33% | Shs Outstand | 78.9M | Perf Week | -0.79% |
| Market Cap | 0.20B | Forward P/E | 23.85 | EPS next Y | -2.62% | Insider Trans | - | Shs Float | 52.0M | Perf Month | -14.38% |
| Enterprise Value | 0.13B | PEG | - | EPS next Q | 0 | Inst Own | 41.07% | Short Float | 8.04% | Perf Quarter | -26.47% |
| Income | 0.02B | P/S | 1.53 | EPS this Y | -46.19% | Inst Trans | -8.37% | Short Ratio | 7.67 | Perf Half Y | -47.15% |
| Sales | 0.13B | P/B | 2.39 | EPS next 5Y | -2.27% | ROA | 16.14% | Short Interest | 4.18M | Perf YTD | -60.69% |
| Book/sh | 1.05 | P/C | 2.96 | EPS past 3/5Y | - | ROE | 21.8% | 52W High | -68.55% ($7.95) | Perf Year | -65.61% |
| Cash/sh | 0.84 | P/FCF | 35.2 | Sales past 3/5Y | 21.56% 16.91% | ROIC | 19.05% | 52W Low | 4.82% ($2.38) | Perf 3Y | 89.39% |
| Dividend Est. | - | EV/EBITDA | 12.57 | EPS Y/Y TTM | -12.12% | Gross Margin | 64.24% | Volatility(W/M) | 3.32% 3.77% | Perf 5Y | -59.61% |
| Dividend TTM | - | EV/Sales | 1.03 | Sales Y/Y TTM | 10.99% | Oper. Margin | 6.67% | ATR (14) | 0.09 | Perf 10Y | -12.59% |
| Dividend Ex-Date | - | Quick Ratio | 5.13 | EPS Q/Q | -72.01% | Profit Margin | 12.39% | RSI (14) | 38.24 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.5 | Sales Q/Q | -4.28% | SMA20 | -2.82% ($2.57) | Beta | 2.09 | Target Price | $9.9 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/11/4 | SMA50 | -13.05% ($2.88) | Rel Volume | 0.64 | Prev Close | $2.54 |
| Employees | 117 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 20.48% -2.45% | SMA200 | -36.5% ($3.94) | Avg Volume(3M) | 0.54M | Price | $2.5 |
| IPO | 2008/6/24 | Option/Short | Yes/Yes | Trades | 1933 | Volume | 348,392 | Change | -1.57% |
🧬 NiaGenesis Biosciences (NAGE) is a science-driven nutraceutical company focused on aging-related health. Founded in 1999 and formerly known as ChromaDex, it is a US-based company that operates consumer products, ingredients, and analytical reference standards businesses centered on Niagen, an NAD precursor ingredient and a key intracellular coenzyme.
Over the past 1 year, on the lower side
69% below its 1-year high.
Traded less than usual. That is 64% of its average volume.
Next earnings report: November 4
5 days to go.
NAGE makes money exceptionally well
Of every $100 in sales, $6.67 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -46.2% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,257. Peers typically go for $835. Compared with its own 2-year average, it is 57% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -59.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 41.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
LOPP Gabelli Love Our Planet & People ETF <0.01% 
QQQS Invesco NASDAQ Future Gen 200 ETF <0.01% 
SQLV Royce Quant Small-Cap Quality Value ETF <0.01% 
BFOR Barrons 400 ETF <0.01% 
SFLO VictoryShares Small Cap Free Cash Flow ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
GRID First Trust Clean Edge Smart Grid 11.5B 
KWH GMO Power Infrastructure ETF 54M 
WATS Corgi Battery Energy Storage Systems ETF - It ranks #39 of 61 in the industry
Based on market cap of $198M.
USNA#36 Usana Health Sciences Inc $265M PER - 
OTLY#37 Oatly Group AB ADR $255M PER - 
NATR#38 Nature's Sunshine Products Inc $216M PER 12.2 NAGE#39 Niagen Bioscience Inc $198M PER 13.3 
BGS#40 B&G Foods Inc $184M PER - 
FAQ
What kind of company is NAGE?
NAGE belongs to the Consumer Defensive sector and operates in the Packaged Foods industry.
What is the market cap of NAGE?
The market cap of NAGE is approximately $198M, ranking 4,037 within its sector.
What is the P/E ratio of NAGE?
NAGE has a P/E ratio of approximately 13.3x, which can be used to assess its valuation relative to the Consumer Defensive sector average.
What is the 52-week high and low for NAGE?
NAGE has recorded a 52-week high of $7.95 and a low of $2.38.
